Karakasis, P.; Theofilis, P.; Vlachakis, P.K.; Grigoriou, K.; Patoulias, D.; Antoniadis, A.P.; Fragakis, N.
Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction. Pharmaceutics 2025, 17, 1028.
https://doi.org/10.3390/pharmaceutics17081028
AMA Style
Karakasis P, Theofilis P, Vlachakis PK, Grigoriou K, Patoulias D, Antoniadis AP, Fragakis N.
Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction. Pharmaceutics. 2025; 17(8):1028.
https://doi.org/10.3390/pharmaceutics17081028
Chicago/Turabian Style
Karakasis, Paschalis, Panagiotis Theofilis, Panayotis K. Vlachakis, Konstantinos Grigoriou, Dimitrios Patoulias, Antonios P. Antoniadis, and Nikolaos Fragakis.
2025. "Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction" Pharmaceutics 17, no. 8: 1028.
https://doi.org/10.3390/pharmaceutics17081028
APA Style
Karakasis, P., Theofilis, P., Vlachakis, P. K., Grigoriou, K., Patoulias, D., Antoniadis, A. P., & Fragakis, N.
(2025). Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction. Pharmaceutics, 17(8), 1028.
https://doi.org/10.3390/pharmaceutics17081028
